The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain
Top Cited Papers
Open Access
- 31 August 2017
- journal article
- review article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 43 (1) , 52-79
Abstract
A great need exists for the development of new medications to treat pain resulting from various disease states and types of injury. Given that the endogenous cannabinoid (that is, endocannabinoid) system modulates neuronal and immune cell function, both of which play key roles in pain, therapeutics targeting this system hold promise as novel analgesics. Potential therapeutic targets include the cannabinoid receptors, type 1 and 2, as well as biosynthetic and catabolic enzymes of the endocannabinoids N-arachidonoylethanolamine and 2-arachidonoylglycerol. Notably, cannabinoid receptor agonists as well as inhibitors of endocannabinoid-regulating enzymes fatty acid amide hydrolase and monoacylglycerol lipase produce reliable antinociceptive effects, and offer opioid-sparing antinociceptive effects in myriad preclinical inflammatory and neuropathic pain models. Emerging clinical studies show that ‘medicinal’ cannabis or cannabinoid-based medications relieve pain in human diseases such as cancer, multiple sclerosis, and fibromyalgia. However, clinical data have yet to demonstrate the analgesic efficacy of inhibitors of endocannabinoid-regulating enzymes. Likewise, the question of whether pharmacotherapies aimed at the endocannabinoid system promote opioid-sparing effects in the treatment of pain reflects an important area of research. Here we examine the preclinical and clinical evidence of various endocannabinoid system targets as potential therapeutic strategies for inflammatory and neuropathic pain conditions.Keywords
This publication has 316 references indexed in Scilit:
- Full Inhibition of Spinal FAAH Leads to TRPV1-Mediated Analgesic Effects in Neuropathic Rats and Possible Lipoxygenase-Mediated Remodeling of Anandamide MetabolismPLOS ONE, 2013
- Analgesic Effect of a Mixed T-Type Channel Inhibitor/CB2 Receptor AgonistMolecular Pain, 2013
- Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trialThe Journal of Headache and Pain, 2012
- Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti‐inflammatory cytokine responses in neuropathic rats exhibiting relief from allodyniaBrain and Behavior, 2012
- Effects of anandamide in migraine: data from an animal modelThe Journal of Headache and Pain, 2011
- Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory PainChemistry & Biology, 2009
- Interactions between Δ9-tetrahydrocannabinol and μ opioid receptor agonists in rhesus monkeys: discrimination and antinociceptionPsychopharmacology, 2008
- A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-ArachidonoylglycerolChemistry & Biology, 2007
- Low dose combination of morphine and Δ9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptorsEuropean Journal of Pharmacology, 2007
- OsteoarthritisJournal of Cellular Physiology, 2007